Cytotoxic T cell recognition of an HIV-1 reverse transcriptase variant peptide incorporating the K103N drug resistance mutation

AIDS Research and Therapy

Volumn 3, Issue 1, 2006, Pages

  Mahnke, Lisa ^a   Clifford, David ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIRETROVIRUS AGENT; ASPARAGINE; EFAVIRENZ; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LAMIVUDINE; LYSINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG CLASSIFICATION; DRUG DESIGN; DRUG EXPOSURE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE MUTATION; GENETIC SELECTION; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIVIDUALITY; MALE; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN VARIANT; T LYMPHOCYTE ACTIVATION; WILD TYPE;

EID: 33750184214     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-3-21     Document Type: Article

References (21)

1. Walker BD, Charkrabarti S, Moss B, Paradis TJ, Flynn T, Durno AG, Blumberg RS, Kaplan JC, Hirsch MS, Schooley RT: HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987, 328:345-382.
2. Draenert R, Verrill CL, Tang Y, Allen TM, Wurcel AG, Boczanowski M, Lechner A, Kim AY, Suscovich T, Brown NV, Addo MM, Walker BD: Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type I infection. J Virol 2004, 78:630-41.
3. Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, Dunphy E, Liebl ME, Emerson C, Wilson N, Kunstman KJ, Wang X, Allison DB, Hughes AL, Desrosiers RC, Altman JD, Wolinsky SM, Sette A, Watkins DI: Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000, 407:386-90.
4. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, Rosenberg ES, Nguyen T, Allen R, Trocha A, Altfeld M, He S, Bunce M, Funkhouser R, Pelton SI, Burchett SK, McIntosh K, Korber BT, Walker BD: Evolution and transmission of stable CTL escape mutations in HIV. Nature 2001, 412:334-338.
5. Kelleher AD, Long C, Holmes ED, Allen RL, Wilson J, Conlon C, Workman C, Shanunak S, Olson K, Goulder P, Brander D, Ogg G, Sullivan JS, Dyer W, Jones I, McMichael AJ, Rowland-Jones S, Phillips RE: Clustered mutation in HIV-I gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001, 193:375-386.
6. Walker BD, Flexner C, Paradis TJ, Fuller TC, Hirsch MS, Schooley RT, Moss B: HIV-I reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science 1988, 240:64-6.
7. Altfeld M, Addo MM, Shankarappa R, Lee PK, Allen TM, Yu XG, Rathod A, Harlow J, O'Sullivan K, Johnston MN, Goulder PJ, Mullins JI, Rosenberg ES, Brander C, Korber B, Walker BD: Enhanced detection of human immunodeficiency virus type I-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol 2003, 77:7330-40.
8. Rudolph MG, Stanfield RL, Wilson IA: How TCRs bind MHCs, peptides, and coreceptors. Ann Review Immunol 2006, 24:419-466.
9. Schmitt M, Harrer E, Goldwich A, Bauerle M, Graedner I, Kalden JR, Harrer T: Specific recognition of lamivudine-resistant HIV-I by cytotoxic T lymphocytes. AIDS 2000, 14:643-8.
10. Samri A, Haas G, duntze J, Bouley JM, Calvez V, Katlama C, Autran B: Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type I-specific cytotoxic T cells. J Virol 2000, 74:9306-9312.
11. Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sallberg M, Ortiz GM, Demarest JF, Leigler T, Grant RM, Martin JN, Nixon DF: Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type I protease gene. J Virol 2003, 77:6743-6752.
12. Clavel F, Hance AJ: HIV drug resistance. NEJM 2004, 350:1023-1035.
13. Los Alamos National Laboratory HIV Sequence Database [http://hiv-web.lanl.gov/content/hiv-db/mainpage.html]
14. Los Alamos HIV Database, HIV Molecular Immunology [http://hiv-web.lanl.gov/content/immunology]
15. Karisson AC, Martin JN, Younger SR, Bredt BM, Epling L, Ronquillo R, Varma A, Deeks SG, McCuneJM, Nixon DG, Sinclair E: Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods 2003, 283:141-153.
16. Immune Epitope Database and Analysis Resource [http://www.immuneepitope.org]
17. Peters B, Sidney J, Bourne P, Bui HH, Buus S, Doh G, Fleri W, Kronenberg M, Kubo R, Lund O, Nemazee D, Ponomarenko JV, Sathiamurthy M, Schoenberger S, Stewart S, Surko P, Way S, Wilson S, Sette A: The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol 2005, 3:e91.
18. Ribaudo HJ, Hass DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP: Pharmacogenetics of plaslma efavirenz exposure after treatment discontinuation: an adult AIDS Clinical Trials Group study. Clin Infect Dis 2006, 42:401-407.
19. Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang XV, Ellis D, Becker MF, Laut AL, George HJ, Spalding DR, Hollis G, Abremski K: Human immunodeficiency virus type I mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000, 44:2475-2484.
20. John M, Moore CB, James IR, Mallall SA: Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-I. Antivir Ther 2005, 10:551-555.
21. Mason RD, Bowmer MI, Howley CM, Gallant M, Myers JCE, Grant MD: Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-I Pol epitopes. J Immunol 2004, 172:7212-7219.